Advances in the diagnosis and treatment of maple syrup urine disease: Experience in Galicia (Spain);Avances en el diagnóstico y tratamiento de la enfermedad de jarabe de arce, experiencia en Galicia

Anales de Pediatria

Volumn 67, Issue 4, 2007, Pages 337-343

  Couce Pico, M L ^a   Castineiras Ramos D E ^a   Boveda Fontan M D ^a   Iglesias Rodriguez A J ^a   Cocho De Juan, J A ^a   Fraga Bermudez J M ^a  

^a Instituto de Salud Carlos III   (Spain)

Author keywords

Branched chain amino acids; Dried blood spot sample; Maple syrup urine disease (MSUD); Neonatal Screening; Tandem mass spectrometry

Indexed keywords

LEUCINE;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; INTELLIGENCE QUOTIENT; MALE; MAPLE SYRUP URINE DISEASE; NEWBORN SCREENING; SPAIN; TANDEM MASS SPECTROMETRY;

EID: 35448986517     PISSN: 16954033     EISSN: 16959531     Source Type: Journal    
DOI: 10.1157/13110606     Document Type: Article

References (21)

1. Chuang DT, Shih VE. Maple syrup urine disease (branched-chain ketoaciduria). En: Scriver Ch R, Beaudet AL, Sly WS, Valle MD, editors. The metabolic & molecular bases of inherited disease. 8th ed. New York: McGraw-Hill; 2001. p. 971-2005.
2. a ed. Madrid: Ergón; 2006. p. 367-75.
3. Chance DH, Kalas TA, Naylor EW. Use of tandem mass spectrometry for multianalyte screening of dried blood speciemens from newborns. Clin Chem. 2003;49:1797-817.
4. Zytkovicz HT, Fitzgerald FE, Marsden D, Larson AC, Shih, EV, Johnson MD, et al. Tandem mass spectrometric analysis for amino, organic and fatty acid disorders in newborn dried blood spots: a two-years summary from the New England Newborn Screening Program. Clin Chem. 2001;47:1945-55.
5. Chance DH, Kalas TA, Naylor EW. The application of tandem mass spectrometry to neonatal screening for inherited disorders of intermediary metabolism. Annu Rev Genomics Hum Genet. 2002;3:17-45.
6. Huang HP, Chu KL, Chien YH, Wei ml, Wu ST, Wang SF, et al. Tandem mass neonatal screening in Taiwan-report from one center. J Formos Med Assoc. 2006;105:882-6.
7. Lynch CJ, Patson BJ, Anthony J, Vaval A, Jefferson LS, Vary TC. Am J Physiol Endocrinol Metab. 2002;283:E503-13.
8. Dirección Xeral de Saúde Pública. Guías de Saúde Pública. Serie II. Sección E. Endocrinas e Metab.: Informe 3 "Actualización del Programa Gallego para la detección precoz de enfermedades endocrinas y metabólicas en período neonatal. Resultados 1995-2005". Santiago de Compostela: Conselleria de Sanidade, Xunta de Galicia; 2006.
9. Wendel U, Ogier de Baulny H. Branched-Chain organic acidurias/ acidemias. En: Fernandes J, Saudubray JM, Van Den Berghe G, Walter JH, editors. Inborn metabolic diseases. Diagnosis and treatment. 4ed. Berlín: Springer; 2006. p. 245-62.
10. Morton DH, Strauss KA, Robinson DL, Puffenberger EG, Kelley RI. Diagnosis and treatment of maple syrup disease: a study of 36 patients. Pediatrics. 2002;109:999-1008.
11. Simon E, Fingerhut R, Baumkötter J, Konstantopoulou V, Ratschmann R, Wendel U. Maple syrup urine disease: favourable effect of early diagnosis by newborn screening on the neonatal course of the disease. J Inherit Metab Dis. 2006;29: 532-7.
12. Heldt K, Schwahn B, Marquardt I, Grotzke M, Wendel U. Diagnosis of MSUD by newborn screening allows early intervention without extraneous detoxification. Mol Genet Metab. 2005;84:313-6.
13. Hoffmann B, Helbling Ch, Schadewaldt P, Wendel U. Impact of longitudinal plasma leucine levels on the intellectual outcome in patients with classic MSUD. Pediatr Res. 2006;59: 17-20.
14. Koga Y, Iwanaga T, Yoshida I, Yoshino M, Kaneko S, Kato H. Maple syrup urine disease: nutritional management by intravenous hyperalimentation and uneventual course after surgical repair of dislocation on the hip. J Inher Metab Dis. 1998;21:177-8.
15. Simon E, Flaschker P, Schadewaldt P, Langenbeck U, Wendel U. Variant maple syrup urine disease (MSUD) - The entire spectrum. J Inherit Metab Dis. 2006;29:716-24.
16. Nellis MM, Kasinski A, Carlson M, Allen R, Schaefer AM, Schwartz EM, et al. Relationship of causative genetic mutations in maple syrup urine disease with their clinical expression. Mol Genet Metab. 2003;80:189-95.
17. Chuang JL, Wynn RM, Moss CC, Song J, Li J, Awad N, et al. Structural and biochemical basis for novel mutations in homozygous Israeli maple syrup urine disease patients. J Biol Chem. 2004;279:17792-800.
18. Rodríguez-Pombo P, Merinero B, Navarrete R, Pérez- Cerdá C, Ugarte M. Molecular and biochemical analisis of MSUD spanish variants. J Inherit Metab Dis. 2005;28:53.
19. Rodríguez-Pombo P, Navarrete R, Merinero B, Gómez-Puertas P, Ugarte M. Mutational spectrum of maple syrup urine disease in Spain. Hum Mutat. 2006;27:715.
20. Henneke M, Flaschker N, Helbling C, Muller M, Schadewaldt P, Gatner J, et al. Human Mutat. 2003;22:417.
21. Simon E, Fingerhurt R, Baumkötter J, Konstantopoulou V, Ratschmann R, Wendel U. Maple syrup urine disease: Favourable effect of early diagnosis by newborn screening on the neonatal course or the disease. J Inherit Metab Dis. 2006;29:532-7.